Get the Stockscreener App
2.57
3.75%
-0.10
After Hours:
2.54
-0.03
-1.17%
Iovance Biotherapeutics Inc stock is traded at $2.57, with a volume of 13.54M.
It is down -3.75% in the last 24 hours and up +49.42% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.67
Open:
$2.62
24h Volume:
13.54M
Relative Volume:
0.82
Market Cap:
$858.21M
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-1.5389
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-21.88%
1M Performance:
+49.42%
6M Performance:
-56.07%
1Y Performance:
-70.56%
1-Day Range:
$2.51
$2.65
1-Week Range:
$2.51
$3.45
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.57 | 891.60M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - Insider Monkey
Exit strategy if you’re trapped in Iovance Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser
What is the risk reward ratio of investing in Iovance Biotherapeutics Inc. stockEarnings Report Planner For 2025 - jammulinksnews.com
Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Conservative Asset Allocation Risk Analysis - Newser
Will Iovance Biotherapeutics Inc. price bounce be sustainableSafe Momentum Strategy With Trend Analysis - Newser
Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis
Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com
Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade
Is Iovance Biotherapeutics Stock Due for a Big Rally? - Mitrade
Using AI based signals to follow Iovance Biotherapeutics Inc.Chart Pattern Recognition for Profit Timing - Newser
How to monitor Iovance Biotherapeutics Inc. with trend dashboardsReliable Setup Screener with Low Risk - Newser
Is Iovance Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Optimized Watchlist With Daily Adjustments - Newser
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionReal Time Trade Execution Alert Plan - Newser
Can Iovance Biotherapeutics Inc. rally from current levelsFree Multi-Bagger Potential Stock Forecast Tools - Newser
Price momentum metrics for Iovance Biotherapeutics Inc. explainedMomentum Prediction Based on AI Backtesting - Newser
Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - Yahoo Finance
Iovance Biotherapeutics’ SWOT analysis: stock faces challenges amid promising data - Investing.com
What are the latest earnings results for Iovance Biotherapeutics Inc.Tremendous gains - jammulinksnews.com
Does Iovance Biotherapeutics Inc. stock perform well during market downturnsRecord-breaking capital gains - jammulinksnews.com
How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser
What are Iovance Biotherapeutics Inc. company’s key revenue driversIdentify winners with top-tier analysis - jammulinksnews.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com
Decoding Iovance Biotherapeutics: A TIL Breakout or Premature Optimism? - AInvest
Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛
Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating - AInvest
What analysts say about Iovance Biotherapeutics Inc. stockUnprecedented market success - PrintWeekIndia
Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
About Us - FinancialContent
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics: A Contrarian Bet on TIL Therapy Amid Regulatory Hurdles for Rivals - AInvest
Iovance’s Big Bet On Cancer Hits Bumps, But The Payoff Could Be Huge - Finimize
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics Benefits from Replimune FDA Setback, Maintains Buy Rating - AInvest
Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Nasdaq
Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView
Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest
Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade
Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛
Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com
Analyst Expectations For Iovance Biotherapeutics's Future - 富途牛牛
Iovance Biotherapeutics (IOVA.O) Soars 10.22% on FDA Validation, CEO Appointment - AInvest
Where are the Opportunities in (IOVA) - news.stocktradersdaily.com
What drives Iovance Biotherapeutics Inc. stock priceFast-track wealth growth - jammulinksnews.com
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Iovance Biotherapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - jammulinksnews.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):